^
    almost2years
    BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=90, Not yet recruiting, Shanghai Gopherwood Biotech Co., Ltd.
    New P1/2 trial • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR negative
    |
    Focus V (anlotinib) • BR790